From: Effect of bevacizumab combined with chemotherapy on SDF-1 and CXCR4 in epithelial ovarian cancer and its prognosis
Group
Group A (34)
Group B (34)
P
CR
5(14.71)
11(32.35)
0.086
PR
10(29.42)
16(47.06)
0.134
SD
3(8.82)
0.031
PD
9(26.47)
4(11.76)
0.123
Total effective rate of treatment [n(%)]
28(82.36)
0.002